SCHEDULE 13G/A: Commodore Capital Discloses 6.3% Stake in Tyra Biosciences

Commodore Capital LP and its affiliates have reported a 6.3% beneficial ownership stake in Tyra Biosciences, Inc., totaling 3,375,000 shares of common stock.

Summary

• Commodore Capital LP, along with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, collectively reported beneficial ownership of 3,375,000 shares of Tyra Biosciences, Inc. common stock.
• This ownership represents 6.3% of Tyra Biosciences, Inc.'s outstanding common stock.
• The ownership percentage is calculated based on 53,318,198 common shares reported as issued and outstanding by Tyra Biosciences, Inc. as of September 30, 2025.
• The reporting persons share both voting and dispositive power over all 3,375,000 shares.
• The securities were not acquired or held for the purpose of changing or influencing the control of Tyra Biosciences, Inc.

Sentiment

Score: 6

Explanation: The disclosure of a 6.3% beneficial ownership by an investment firm like Commodore Capital can be interpreted as a vote of confidence in Tyra Biosciences, Inc., which is generally a positive indicator for investors. However, the filing itself is a factual report of ownership and does not contain performance or strategic updates.

Positives

• A significant investment by an institutional investor like Commodore Capital, holding 6.3% of outstanding shares, may signal confidence in Tyra Biosciences, Inc.'s long-term prospects.

Negatives

• This filing does not contain information that would typically be categorized as negative, as it is a disclosure of beneficial ownership rather than a performance report.

Risks

• The concentration of 6.3% of the common stock in the hands of a single investment group, even if passive, introduces a potential for future influence on corporate decisions or market liquidity if the stake were to change significantly.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 6.3% stake may increase investor confidence and potentially influence trading activity.
• Company Management: Awareness of a significant shareholder may influence strategic decisions, although the filing states the stake is not for control.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant beneficial ownership stake by Commodore Capital LP and its affiliates in Tyra Biosciences, Inc. While a substantial institutional investment can be a positive signal, this filing is purely a disclosure of ownership and does not provide new financial results, strategic updates, or operational performance metrics that would warrant a stronger buy or sell recommendation. Investors should consider this information as part of a broader due diligence process, noting the presence of a significant institutional holder, but without additional context, a 'hold' recommendation is appropriate as it doesn't fundamentally alter the investment thesis based solely on this disclosure.

Keywords

Tyra Biosciences, Commodore Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Equity Stake, Biotechnology